dc.contributor.author |
Seine, Adrian J |
|
dc.contributor.author |
Baird, Elizabeth Ann |
|
dc.contributor.author |
Chan, Lydia |
|
dc.contributor.author |
Davis, Anne |
|
dc.contributor.author |
Greig, Deborah |
|
dc.contributor.author |
Judd, Lissa Elaine |
|
dc.contributor.author |
Mahon, Caroline |
|
dc.contributor.author |
Oakley, Amanda |
|
dc.contributor.author |
Rademaker, Marius |
|
dc.contributor.author |
Reiche, Louise |
|
dc.contributor.author |
Stanway, Amy Donna |
|
dc.contributor.author |
Cheng, Harriet S |
|
dc.coverage.spatial |
Australia |
|
dc.date.accessioned |
2022-05-09T02:31:45Z |
|
dc.date.available |
2022-05-09T02:31:45Z |
|
dc.date.issued |
2021-11 |
|
dc.identifier.citation |
(2021). Australasian Journal of Dermatology, 62(4), 489-495. |
|
dc.identifier.issn |
0004-8380 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/59090 |
|
dc.description.abstract |
<h4>Background</h4>Patch testing is the gold standard diagnostic test for allergic contact dermatitis and needs to be relevant to the region and the population being tested. The aim of this study was to develop a specific New Zealand baseline series (NZBS).<h4>Method</h4>We performed a retrospective case note review of patients attending four regional patch test centres between 2008 and 2020. Demographic and diagnostic information was collected for each patient along with results of patch testing. Using the results of this review, a group of 11 dermatologists with an interest in contact dermatitis agreed on a core group of allergens for inclusion in an NZBS, based on the frequency of positive reactions and allergens of interest. The remaining potential allergens were ranked by each dermatologist using an online questionnaire, with inclusion in the final NZBS by consensus.<h4>Results</h4>Results from 2402 patients (67% female, mean age 44 years) from Auckland, Wellington, Palmerston North and Christchurch were collated. The 10 most frequent positive (relevant and non-relevant) allergens were nickel sulfate (22.0%), fragrance mix I (8.6%), cobalt chloride (7.3%), Myroxylon pereirae (5.6%), colophonium (5.1%), p-phenylenediamine (4.9%), methylisothiazolinone/methylchloroisothiazolinone (4.1%), fragrance mix II (3.9%), potassium dichromate (3.5%) and methylisothiazolinone (3.4%). Based on these results, a core series of 30 allergens was developed, with an additional 30 allergens added to form the extended series (total 60 allergens).<h4>Conclusion</h4>The baseline series of patch test allergens for routine use in New Zealand (NZBS) is based on national patch test data and expert consensus. |
|
dc.format.medium |
Print-Electronic |
|
dc.language |
eng |
|
dc.publisher |
Wiley |
|
dc.relation.ispartofseries |
The Australasian journal of dermatology |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.subject |
Humans |
|
dc.subject |
Dermatitis, Allergic Contact |
|
dc.subject |
Allergens |
|
dc.subject |
Patch Tests |
|
dc.subject |
Retrospective Studies |
|
dc.subject |
Adult |
|
dc.subject |
Middle Aged |
|
dc.subject |
New Zealand |
|
dc.subject |
Female |
|
dc.subject |
Male |
|
dc.subject |
Young Adult |
|
dc.subject |
allergic contact dermatitis |
|
dc.subject |
baseline series |
|
dc.subject |
patch test |
|
dc.subject |
Clinical Research |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Dermatology |
|
dc.subject |
FRAGRANCE MIX II |
|
dc.subject |
HYDROXYISOHEXYL 3-CYCLOHEXENE CARBOXALDEHYDE |
|
dc.subject |
CONTACT-DERMATITIS |
|
dc.subject |
ALLERGY |
|
dc.subject |
ESSCA |
|
dc.subject |
1103 Clinical Sciences |
|
dc.subject |
1114 Paediatrics and Reproductive Medicine |
|
dc.title |
A baseline patch test series for New Zealand. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1111/ajd.13673 |
|
pubs.issue |
4 |
|
pubs.begin-page |
489 |
|
pubs.volume |
62 |
|
dc.date.updated |
2022-04-18T20:10:24Z |
|
dc.rights.holder |
Copyright: The author |
en |
dc.identifier.pmid |
34293187 (pubmed) |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/34293187 |
|
pubs.end-page |
495 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Journal Article |
|
pubs.elements-id |
861504 |
|
pubs.org-id |
Medical and Health Sciences |
|
pubs.org-id |
School of Medicine |
|
pubs.org-id |
Medicine Department |
|
dc.identifier.eissn |
1440-0960 |
|
pubs.record-created-at-source-date |
2022-04-19 |
|
pubs.online-publication-date |
2021-07-22 |
|